Berkeley Heights, N.J. – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced today, March 3, 2026, that its common stock has been approved for transfer from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the higher tier is expected to begin at the market open today, continuing under the existing ticker symbol “TNXP.” This move signals a significant step forward for the biotechnology company, reflecting its adherence to more stringent financial and corporate governance standards.
The uplisting to the Nasdaq Global Select Market is anticipated to increase the company’s visibility among institutional investors, potentially improving liquidity and broadening its overall market recognition. Tonix Pharmaceuticals, a fully integrated, commercial-stage biotechnology company, has been focused on developing treatments for central nervous system (CNS) and immunology disorders. The company’s CEO, Seth Lederman, M.D., described the move as “an important milestone,” expressing confidence in leveraging the enhanced platform to drive growth and shareholder value.
The Nasdaq Global Select Market represents the highest tier of Nasdaq’s market structure, reserved for companies that meet elevated requirements in financial performance, liquidity and corporate governance. According to Nasdaq, companies listed on this tier often experience increased trading volumes and greater access to investment from institutional sources. Meeting these standards can also be interpreted by the market as a sign of financial and operational maturity.
Tonmya™ and a Growing Pipeline
Tonix Pharmaceuticals’ recent success is largely tied to the launch of TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s flagship product and the first new treatment for fibromyalgia approved in over 15 years. Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. The Mayo Clinic estimates that millions of adults in the United States are affected by fibromyalgia.
Beyond TONMYA™, Tonix maintains a commercial infrastructure supporting its existing acute migraine treatments, Zembrace® SymTouch® and Tosymra®. The company is actively expanding its research and development efforts, currently conducting Phase 2 clinical trials to evaluate TONMYA’s potential in treating major depressive disorder and acute stress disorder. This strategy of maximizing the potential of its existing compounds demonstrates a commitment to innovation and expanding treatment options.
Expanding into Rare Diseases and Immunology
Tonix’s pipeline extends beyond CNS disorders, encompassing treatments for rare diseases and immunological conditions. TNX-2900 is currently Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder that causes developmental delays, behavioral problems, and a constant feeling of hunger. The company is also developing TNX-4800, a monoclonal antibody aimed at Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection.
These diverse programs highlight Tonix’s commitment to addressing unmet medical needs across a range of therapeutic areas. The development of TNX-1500, in particular, could offer a significant advancement in preventing organ rejection, a major challenge in transplantation medicine.
Financial Performance and Future Outlook
As of 11:40 AM EST on March 3, 2026, Tonix Pharmaceuticals’ stock was trading at $13.86, down $0.12 (-0.86%), according to Yahoo Finance. The company’s market capitalization currently stands at $177.243 million. While the stock has experienced significant volatility in recent years – with a 5-year loss of 100% – it has seen a substantial 87.80% gain over the past year.
Tonix’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on March 18, 2025, provides further details on the company’s financial performance and future strategies. Investors can access this report and other SEC filings on the SEC’s website.
The company is scheduled to release its next earnings report on or around March 17, 2026. This report will provide further insight into Tonix’s financial performance and progress on its clinical development programs.
Disclaimer: This article is for informational purposes only and does not constitute financial or medical advice. Investing in biotechnology companies carries inherent risks. Consult with a qualified financial advisor before making any investment decisions.
Share this article with colleagues and friends interested in the biotechnology sector and the progress of Tonix Pharmaceuticals. Your feedback is welcome in the comments section below.
